CORRECTED: Feeling Heat from Affy, Packard Nixes Plans to Sell DNA Chips | GenomeWeb

This story was corrected on January 17 to more accurately reflect Packard BioScience’s microarray strategy. The company has cancelled plans to sell DNA chips, not microarrays, as previously reported.

SAN FRANCISCO, Jan 8 – Packard BioScience has cancelled plans to commercialize DNA chips after determining that Affymetrix’ domination in the market was too formidable, a company spokesman said Monday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.